Spyre Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing extended half-life antibodies for inflammatory bowel disease and rheumatic diseases. Its 8-K reports furnish financial results, Regulation FD clinical presentations, and material-event disclosures tied to SPY001, SPY002 and SPY003, including SKYLINE and SKYWAY program updates.
Offering-related filings describe common-stock issuance activity, underwriting agreements, shelf-registration use, proceeds for clinical development, manufacturing and general corporate purposes, and the company’s listed common stock. Proxy materials cover board and compensation matters, equity awards and public-company governance, while periodic and event reports address liquidity, research and development spending, clinical-trial risks and capital-structure disclosures.
Spyre Therapeutics, Inc. CFO Scott L. Burrows reported an option exercise-and-sale sequence on August 3, 2026. He exercised stock options for 7,500 shares of common stock at an exercise price of $14.50 per share, then sold 7,500 shares in three transactions at weighted average prices of $95.21, $96.30 and $97.10, all pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. Following the transactions, he continues to hold options covering 344,857 shares that expire on September 1, 2033 and 67,476 restricted stock units vesting in two equal installments on September 1, 2026 and 2027, subject to continued employment.
Spyre Therapeutics, Inc. CEO Cameron Turtle sold a total of 15,000 shares of common stock on August 3, 2026 in five open-market transactions under a Rule 10b5-1 trading plan adopted on June 20, 2025, at weighted average prices between $93.97 and $97.46 per share.
The sales occurred across trade ranges from $93.42 to $97.47 per share. The reported holdings include 58,108 shares that vest in monthly installments through November 2026, subject to continued service.
Spyre Therapeutics reported second quarter 2026 results and advanced its immunology pipeline. Positive topline Phase 2 induction data for SPY001 and SPY002 in ulcerative colitis showed statistically significant Robart’s Histopathology Index reductions of 9.2 and 10.7 points with robust clinical remission and endoscopic improvement rates and a safety profile consistent with in-class comparators.
The SKYWAY Phase 2 basket trial of anti-TL1A antibody SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis has completed enrollment, with proof-of-concept readouts expected from September through late 2026. Cash, cash equivalents and marketable securities were $1,145.3 million as of June 30, 2026, including $435.2 million in net proceeds from an April equity offering, supporting an expected cash runway into the second half of 2029. Net loss for the quarter was $36.2 million, as higher R&D spend of $65.5 million and G&A of $16.1 million were partially offset by a $40.0 million milestone gain on a legacy asset.
Spyre Therapeutics, Inc. reported a net loss of $36.2 million for the quarter ended June 30, 2026 and $105.2 million for the first half of 2026, reflecting heavy investment in its immunology pipeline. Research and development expenses rose to $65.5 million in the quarter and $125.9 million year-to-date, driven by manufacturing and clinical trial spending in IBD and rheumatic disease programs.
Results include a $40.0 million quarterly gain ($70.0 million year-to-date) from milestone payments on the 2023 sale of pegzilarginase rights, partly offset by a $34.9 million increase in the contingent value right liability tied to those legacy assets. Liquidity strengthened through a $435.2 million April 2026 underwritten equity offering and $9.7 million of at-the-market sales; cash, cash equivalents and marketable securities totaled $1.1 billion as of June 30, 2026, which management expects to fund operations for at least one year. The company remains a clinical-stage biotech with no product revenue and states it will need additional financing to complete development and commercialization.
SYRE insider Scott Burrows filed a notice to sell 30,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, related to an exercise of stock options for cash on 08/03/2026. The filing also lists sales during the prior three months, including 7,500 shares for $658,043.00 on 07/01/2026 under a 10b5-1 plan, 15,000 shares for $1,307,000.00 on 06/25/2026, and 7,500 shares for $532,948.25 on 06/01/2026.
Spyre Therapeutics, Inc. Chief Financial Officer Scott L. Burrows executed a pre-planned option exercise and share sale. On July 1, 2026, he exercised stock options covering 7,500 shares of common stock at $14.50 per share and sold 7,500 shares in open-market transactions at weighted average prices of $87.55 and $88.37. These trades were made under a Rule 10b5-1 trading plan adopted on November 10, 2025. After the transactions, he directly holds 97,994 common shares, plus 67,476 restricted stock units that vest in 2026 and 2027 and 352,357 remaining option shares expiring in 2033.
Spyre Therapeutics, Inc. Chief Medical Officer Sheldon Sloan exercised options to acquire 8,334 shares of common stock at an exercise price of $27.46 per share, then sold the same 8,334 shares in open-market transactions.
The sales occurred on July 1, 2026 at weighted average prices of $87.52 and $88.34 per share, with individual trades ranging from $87.03 to $88.95, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 20, 2025. Following these transactions, Sloan reported no directly held common shares and 305,000 stock options outstanding, part of an option grant for 400,000 shares scheduled to fully vest over four years and expiring on October 1, 2034.
Spyre Therapeutics, Inc. Chief Executive Officer Cameron Turtle sold 15,000 shares of common stock in three open‑market transactions on July 1, 2026. The sales were executed at weighted average prices around $87–$89 per share and were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on June 20, 2025.
Following these transactions, Turtle holds 582,540 shares of Spyre Therapeutics common stock directly. This amount includes 72,623 shares that vest in monthly installments through November 2026, contingent on his continued service with the company.